Blockbusters join TGA's review list

Posted 17 March 2025 AM

The TGA has accepted three drug applications for review this month, including a blockbuster hopeful and expansions on two mega-blockbusters.

Sanofi's type 1 diabetes drug Tzield is being considered to delay the onset of diabetes. It's a CD3-directed antibody, intended for people with Stage 2 Type 1 Diabetes, to delay the progression to Stage 3 and the accompanying health risks, which include life-threatening diabetic ketoacidosis. Patients who progress to Stage 3 eventually require lifelong insulin injections.

To see the whole article, please login